3 Speculative Biotech Stocks to Buy Now
Apr 12th 2013 4:22PM
Updated Apr 12th 2013 5:20PM
Health care analyst Max Macaluso recently sat down with Fool contributor Keith Speights to talk about some of the best speculative biotech plays on the market. Max and Keith discussed three companies that investors should consider: Keryx Pharmaceuticals , Sarepta Therapeutics , and MannKind .
Both Keryx and Sarepta have soared over the last year. Keryx is up a whopping 190% so far in 2013. Meanwhile, Sarepta's shares jumped nearly 50% year-to-date after an amazing run last year.
The nice run by Keryx was powered by high expectations for its kidney disease drug Zerenex. Sarepta's success has stemmed from excitement over its Duchenne muscular dystrophy drug eteplirsen.
MannKind also has enjoyed a great year so far. Shares are up nearly 80% in the first three and a half months of 2013. Investors are eagerly awaiting results from what they hope to be the final study for inhalable insulin product Afrezza.
In this video, Max and Keith talk about the prospects for each of these three speculative biotech stocks.
The future of MannKind?
Will MannKind's disruptive technology revolutionize the way diabetes is treated around the world -- or will the FDA put the kibosh on this product before it even hits the market? In a new premium research report on MannKind, these complex issues are made crystal clear, in addition to showing you why to buy or sell the stock today. To find out more click here to grab your copy today.
The article 3 Speculative Biotech Stocks to Buy Now originally appeared on Fool.com.Fool contributor Keith Speights and Max Macaluso, Ph.D. have no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.